Background pattern of a brain with neural connections

Team Strittmatter

CLEAR-PD: Clearance via Lymphatics & Endocytic Alpha-Synuclein Receptors in Parkinson’s Disease

2026-Present

In Parkinson’s disease (PD), it is clear that the alpha-synuclein protein accumulates in specific neurons, thereby damaging them to cause neurological symptoms. Remarkably, misfolded forms of this alpha synuclein protein spread from one cell to another through the fluid spaces of the brain. Understanding how this extracellular alpha-synuclein is either removed from the brain or delivered to neurons is central to defining PD progression and provides opportunities to modify disease course. Our proposed work seeks molecular approaches to enhance clearance of alpha-synuclein out of the brain and to reduce its interactions with neurons and consequent toxicity, providing potential therapeutic benefit.

Tags
Alpha-synucleinDisease modificationDrug targets

Contributions

Stay tuned—this is where the team’s scientific contributions will be shared.

Accolades

Check back soon to see how this team is being recognized.

In the News

Unraveling Parkinson's. Advancing Precision Medicine.

Aligning Science Across Parkinson’s and The Michael J. Fox Foundation Expand Global Research Initiative with $261M Investment Toward Personalized Treatments

04/28/2026 — Today, Aligning Science Across Parkinson’s (ASAP), in partnership with The Michael J. Fox Foundation for Parkinson’s Research (MJFF), announced $261 million in new grant funding for the Collaborative Research Network (CRN) to map the biological blueprint of Parkinson’s disease and build a standardized toolkit of global research resources that are needed to turn discoveries into treatments.

Our Research Teams

Members of the CRN work diligently to advance our understanding of Parkinson’s disease. Learn more about recent CRN discoveries and achievements.